Biogen and City Therapeutics have announced a partnership worth over $1bn to develop new RNAi therapies. The collaboration ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

These groundbreaking treatments offer new hope for patients to live longer and healthier lives. But ensuring patients benefit ...

Johnson & Johnson (J&J) has announced that a US Food and Drug Administration (FDA) panel of experts has recommended Darzalex ...

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 ...

This sounds entirely obvious but failure to translate this insight into more innovative patient support contributes to the ...

Bristol Myers Squibb (BMS) has announced that its PD-1 immune checkpoint inhibitor Opdivo (nivolumab) has been approved by ...

Results presented at this year’s American Thoracic Society International Conference showed that the trials met their primary ...

Join us on an adventure Alex Legg is one of 15 speakers at Adventures In Pharma on 1 July in London. Join him there to ...

AMICULUM works with the global healthcare industry to bring science to life across the product lifecycle from early opportunity assessment through to launch and beyond. By listening to the changing… ...

Accession was a born from a passion and a vision. A passion to harness the power of market access to ensure patients gain access to life changing medicines and devices….

Everso are a healthcare-focused creative agency composed of a wondrously diverse blend of creative thinkers, passionate about their craft. Together, our aim is to interpret complex and delicate ...